|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GPKOW |
Gene summary for GPKOW |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GPKOW | Gene ID | 27238 |
| Gene name | G-patch domain and KOW motifs | |
| Gene Alias | GPATC5 | |
| Cytomap | Xp11.23 | |
| Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | Q92917 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 27238 | GPKOW | LZE4T | Human | Esophagus | ESCC | 1.46e-02 | 6.02e-02 | 0.0811 |
| 27238 | GPKOW | LZE7T | Human | Esophagus | ESCC | 3.54e-05 | 2.51e-01 | 0.0667 |
| 27238 | GPKOW | LZE8T | Human | Esophagus | ESCC | 3.33e-03 | 1.06e-01 | 0.067 |
| 27238 | GPKOW | LZE20T | Human | Esophagus | ESCC | 5.75e-04 | 1.14e-01 | 0.0662 |
| 27238 | GPKOW | LZE24T | Human | Esophagus | ESCC | 8.50e-07 | 9.97e-02 | 0.0596 |
| 27238 | GPKOW | P2T-E | Human | Esophagus | ESCC | 1.54e-15 | 3.23e-01 | 0.1177 |
| 27238 | GPKOW | P4T-E | Human | Esophagus | ESCC | 3.50e-13 | 2.29e-01 | 0.1323 |
| 27238 | GPKOW | P5T-E | Human | Esophagus | ESCC | 9.96e-16 | 2.20e-01 | 0.1327 |
| 27238 | GPKOW | P8T-E | Human | Esophagus | ESCC | 5.03e-11 | 1.31e-01 | 0.0889 |
| 27238 | GPKOW | P9T-E | Human | Esophagus | ESCC | 6.75e-12 | 2.16e-01 | 0.1131 |
| 27238 | GPKOW | P10T-E | Human | Esophagus | ESCC | 1.17e-15 | 7.49e-02 | 0.116 |
| 27238 | GPKOW | P11T-E | Human | Esophagus | ESCC | 2.68e-10 | 2.99e-01 | 0.1426 |
| 27238 | GPKOW | P12T-E | Human | Esophagus | ESCC | 6.59e-17 | 2.15e-01 | 0.1122 |
| 27238 | GPKOW | P15T-E | Human | Esophagus | ESCC | 2.71e-16 | 1.64e-01 | 0.1149 |
| 27238 | GPKOW | P16T-E | Human | Esophagus | ESCC | 5.59e-17 | 2.94e-01 | 0.1153 |
| 27238 | GPKOW | P17T-E | Human | Esophagus | ESCC | 1.57e-09 | 2.50e-01 | 0.1278 |
| 27238 | GPKOW | P20T-E | Human | Esophagus | ESCC | 2.69e-14 | 2.18e-01 | 0.1124 |
| 27238 | GPKOW | P21T-E | Human | Esophagus | ESCC | 3.10e-08 | 1.52e-01 | 0.1617 |
| 27238 | GPKOW | P22T-E | Human | Esophagus | ESCC | 5.70e-32 | 4.80e-01 | 0.1236 |
| 27238 | GPKOW | P23T-E | Human | Esophagus | ESCC | 3.65e-20 | 4.12e-01 | 0.108 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
| GO:0000375111 | Esophagus | ESCC | RNA splicing, via transesterification reactions | 248/8552 | 324/18723 | 3.05e-30 | 1.49e-27 | 248 |
| GO:0000377111 | Esophagus | ESCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:0000398111 | Esophagus | ESCC | mRNA splicing, via spliceosome | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:000838022 | Liver | HCC | RNA splicing | 313/7958 | 434/18723 | 1.36e-36 | 1.73e-33 | 313 |
| GO:000037522 | Liver | HCC | RNA splicing, via transesterification reactions | 228/7958 | 324/18723 | 1.47e-24 | 4.06e-22 | 228 |
| GO:000037722 | Liver | HCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 224/7958 | 320/18723 | 1.16e-23 | 2.62e-21 | 224 |
| GO:000039822 | Liver | HCC | mRNA splicing, via spliceosome | 224/7958 | 320/18723 | 1.16e-23 | 2.62e-21 | 224 |
| GO:000838020 | Oral cavity | OSCC | RNA splicing | 308/7305 | 434/18723 | 2.43e-42 | 7.70e-39 | 308 |
| GO:000037519 | Oral cavity | OSCC | RNA splicing, via transesterification reactions | 225/7305 | 324/18723 | 5.20e-29 | 2.99e-26 | 225 |
| GO:000037719 | Oral cavity | OSCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 221/7305 | 320/18723 | 5.50e-28 | 2.18e-25 | 221 |
| GO:000039819 | Oral cavity | OSCC | mRNA splicing, via spliceosome | 221/7305 | 320/18723 | 5.50e-28 | 2.18e-25 | 221 |
| GO:0008380110 | Oral cavity | LP | RNA splicing | 237/4623 | 434/18723 | 1.82e-41 | 3.79e-38 | 237 |
| GO:0000375110 | Oral cavity | LP | RNA splicing, via transesterification reactions | 181/4623 | 324/18723 | 1.36e-33 | 1.70e-30 | 181 |
| GO:0000377110 | Oral cavity | LP | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 179/4623 | 320/18723 | 2.48e-33 | 2.22e-30 | 179 |
| GO:0000398110 | Oral cavity | LP | mRNA splicing, via spliceosome | 179/4623 | 320/18723 | 2.48e-33 | 2.22e-30 | 179 |
| GO:0008380112 | Skin | cSCC | RNA splicing | 263/4864 | 434/18723 | 2.45e-53 | 5.13e-50 | 263 |
| GO:0000375112 | Skin | cSCC | RNA splicing, via transesterification reactions | 201/4864 | 324/18723 | 4.07e-43 | 5.10e-40 | 201 |
| GO:0000377112 | Skin | cSCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 197/4864 | 320/18723 | 1.45e-41 | 1.14e-38 | 197 |
| GO:0000398112 | Skin | cSCC | mRNA splicing, via spliceosome | 197/4864 | 320/18723 | 1.45e-41 | 1.14e-38 | 197 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GPKOW | SNV | Missense_Mutation | c.625N>G | p.Leu209Val | p.L209V | Q92917 | protein_coding | tolerated(0.51) | possibly_damaging(0.671) | TCGA-A2-A04U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| GPKOW | SNV | Missense_Mutation | novel | c.32N>A | p.Leu11Gln | p.L11Q | Q92917 | protein_coding | tolerated(0.41) | benign(0) | TCGA-B6-A3ZX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
| GPKOW | SNV | Missense_Mutation | c.1106A>G | p.Asn369Ser | p.N369S | Q92917 | protein_coding | deleterious(0) | benign(0) | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |
| GPKOW | SNV | Missense_Mutation | c.431N>A | p.Ala144Glu | p.A144E | Q92917 | protein_coding | tolerated(0.96) | benign(0.138) | TCGA-D8-A141-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD | |
| GPKOW | SNV | Missense_Mutation | novel | c.243G>T | p.Gln81His | p.Q81H | Q92917 | protein_coding | tolerated(0.09) | possibly_damaging(0.73) | TCGA-PL-A8LV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| GPKOW | SNV | Missense_Mutation | c.525N>A | p.Met175Ile | p.M175I | Q92917 | protein_coding | deleterious(0.01) | probably_damaging(0.973) | TCGA-BI-A0VR-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
| GPKOW | SNV | Missense_Mutation | novel | c.1252N>C | p.Glu418Gln | p.E418Q | Q92917 | protein_coding | tolerated(0.2) | possibly_damaging(0.709) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| GPKOW | SNV | Missense_Mutation | rs377169882 | c.1110G>A | p.Met370Ile | p.M370I | Q92917 | protein_coding | tolerated(0.2) | benign(0) | TCGA-VS-A8QM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| GPKOW | SNV | Missense_Mutation | c.1280N>A | p.Gly427Asp | p.G427D | Q92917 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AY-4070-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | 5-fu | PD | |
| GPKOW | SNV | Missense_Mutation | c.1044N>C | p.Glu348Asp | p.E348D | Q92917 | protein_coding | tolerated(0.28) | benign(0.015) | TCGA-AY-4071-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |